Elevated lipoprotein(a) and increased incidence of restenosis after femoropopliteal PTA. Rationale for the higher risk of recurrence in females?

Atherosclerosis

Volumn 127, Issue 1, 1996, Pages 27-34

  Maca, Thomas ^a   Ahmadi, Ramazanali ^a   Derfler, Kurt ^a   Hörl, Walter Hermann ^a   Koppensteiner, Renate ^a   Minar, Erich ^a   Schneider, Barbara ^b   Stümpflen, Andreas ^a   Ehringer, Herbert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

lipoprotein(a); percutaneous transluminal angioplasty; peripheral arterial occlusive disease; restenosis

Indexed keywords

LIPOPROTEIN A;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMOROPOPLITEAL BYPASS; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

AGED; ANGIOGRAPHY, DIGITAL SUBTRACTION; ANGIOPLASTY, BALLOON; ARTERIAL OCCLUSIVE DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LIPOPROTEIN(A); MALE; POPLITEAL ARTERY; RECURRENCE; RISK FACTORS; SEX FACTORS; ULTRASONOGRAPHY, DOPPLER, DUPLEX;

EID: 0030588591     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)05929-1     Document Type: Article

References (47)

1. [1] Dahlen GH, Guyton JR, Altar MD, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein Lp(a), plasma lipids and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74:758-765.
2. [2] Zenker G, Koltringer P, Bone G, Niederkorn K, Pfeiffer K, Jurgens K. Lipoprotein (a) as a strong indicator for cerebrovascular disease. Stroke 1986;17:942-945.
3. [3] Desmarais RL, Sarembock IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995;91:1403-1409.
4. [4] Hearn JA, Donohue BC, Ba'albaki H, et al. Usefulness of serum Lp(a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992;69:736-739.
5. [5] Tenda K, Saikawa T, Maeda T, et al. The relationship between serum Lp(a) and restenosis after initial elective percutaneous transluminal coronary angioplasty. Jpn Circ J 1993;57:789-795.
6. [6] Stein D, Schoebel FC, Martin J, et al. Fibrinogen and lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty. Clin Hemorheol 1993;13(3):382 (Abstract).
7. [7] Schumacher M, Tiran A, Eber B, Toplak H, Wilders-Truschnig M, Klein W. Lipoprotein(a) is not a risk factor for restenosis after percutaneous transluminal coronary angioptasty. Am J Cardiol 1992;69:572 (Letter).
8. [8] Cooke T, Sheahan MB, Foley D, et al. Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. Circulation 1994;1593-1598.
9. [9] Tyrrell J, Cooke T, Reilly M, et al. Lipoprotein(a) [Lp(a)] and peripheral vascular disease. J Int Med Res 1992;232:349-352.
10. [10] Mölgaard J, Klausen IC, Lassvik C, Faergeman O, Gerdes LU, Olsson AG. Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thromb 1992;12:895-901.
11. [11] Widmann MD, Bauer ES. Lipoprotein(a): a risk factor for peripheral vascular disease. Ann Vasc Surg 1993;7:446-451.
12. [12] Gurakar A, Hoeg JM, Kostner G, Papadopoulos NM, Brewer HB Jr. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 1985;57:293-301.
13. [13] Jäger KA, Phillips DJ, Martin RL, et al. Noninvasive mapping of lower limb arterial lesions. Ultrasound Med Biol 1985;11:515-521.
14. [14] Kostner GM, Avogaro P, Cozzolato G, Marth E, Bittolo-Bon G, Ouinci GB. Lp(a) and the risk for myocardial infarction. J Am Med Assoc 1986;256:2540.
15. R. User's Guide. Version 6. SAS Institute Inc., Cary, NC, 1990.
16. [16] Schneider E, Grüntzig AR, Bollinger A. Long-term results after PTA in 882 consecutive patients with iliac and femoropopliteal obstructions. VASA 1982;11:322-326.
17. [17] Morin JF, Johnston KW, Wasserman L, Andrews D. Factors that determine the long-term results of percutaneous transluminal dilatation for peripheral arterial occlusive disease, J Vasc Surg 1986;4:68-72.
18. [18] Gallino A, Mahler F, Probst P. Nachbur B, Percutaneous transluminal angioplasty of the arteries of the lower limbs: a 5 year follow-up. Circulation 1984;70:619-623.
19. [19] Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH: The role of platelets, thrombin, and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol 1991;16:77-88.
20. [20] Dzau VJ, Gibbons GH. Vascular remodeling: mechanisms and implications. J Cardiovasc Pharm 1993:21 (Suppl 1):1-5.
21. [21] Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991;17:758-69.
22. [22] Herrman, J-PR, Hermans WRM, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the holy grail? (PartI). Drugs 1993;46:18-52.
23. [23] Herrman, J-PR, Hermans WRM, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the holy grail? (PartII). Drugs 1993;46:249-262.
24. [24] Yao JST: Peripheral arterial disease: evaluation in pre-, intra-and postoperative states. In: Felix WR Jr, (ed). Noninvasive Diagnosis of Peripheral Vascular Disease. New York, NY: Raven Press; 1988:145-170.
25. [25] Rutherford RB, Becker GJ. Standards for evaluating and reporting the results of surgical and percutaneous therapy for peripheral arterial disease. Radiology 1991;181:277-281.
26. [26] Leng GC, Whyman MR, Donnan PT, et al. Accuracy and reproducibility of duplex ultrasonography in grading femoropopliteal stenoses. J Vasc Surg 1993;17:510-517.
27. [27] Seifert H, Jäger K. Diagnostic value of duplex scanning in peripheral vascular disease. Vasc Med Rev 1990;1:21-33.
28. [28] Ranke C, Creutzig A, Alexander K. Duplex scanning of the peripheral arteries: correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol 1992;18:433-440.
29. [29] Cossman DV, Ellison JE, Wagner WH, et al. Comparison of contrast arteriography to arterial mapping with color-flow duplex imaging in the lower extremities. J Vasc Surg 1989;10:522-8.
30. [30] Koennecke HC, Fobbe G, Hamed M, Wolf KJ. Diagnostik arterieller Gefäßerkrankungen der unteren Extremitäten mit der farbkodierten Duplexsonographie. Röfo 1989;151:42-46.
31. [31] Polak JF, Karmel MI, Mannick JA, O'Leary DH, Donaldson MC, Whittemore AD. Determination of the extent of lower-extremity peripheral arterial disease with color-assisted duplex sonography. Am J Roentgenol 1990;155:1085-1089.
32. [32] Legemate DA, Teeuwen C, Hoeneveld H, Ackerstaff A, Eikelboom BC. Spectral analysis criteria in duplex scanning of aortoiliac and femoropopliteal arterial disease. Ultrasound Med Biol 1991;17:769-776.
33. [33] Neuerburg-Heusler D, Hennerici M. Gefäßdiagnostik mit Ultraschall. Doppler- und farbkodierte Duplexsonographie der großen Körperarterien und -venen. In: Periphere Arterien: Fehlerquellen und diagnostische Aussage. Stuttgart: Georg Thieme Verlag, 1995;176-182.
34. [34] Johnston KW, Rae M, Hogg-Johnston SA, et al. 5-year results of a prospective study of percutaneous transluminal angioplasty. Ann Surg 1987;206:403-412.
35. [35] Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty: factors influencing long-term success. Circulation 1991; 83 (Suppl.I):70-80.
36. [36] Mahler F, Schneider E, Gallino A, Bollinger A. Combination of suloctidil and anticoagulation in the prevention of reocclusion after femoropopliteal PTA. VASA 1987;16:381-385.
37. [37] Katzenschlager R, Ahrnadi A, Minar E, et al. Femoropopliteal artery: initial and 6 month results of color duplex ultrasound guided percutaneous transluminal angioplasty. Radiology 1996;199:331-334.
38. [38] Hoff HF, Beck GJ, Skibinski CI, et al. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation 1988;77:1238-1244.
39. [39] Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993;260:1655-1658.
40. [40] Minar E, Ahmadi A, Koppensteiner R, et al. Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty. Circulation 1995;91:2167-2173.
41. [41] Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-305.
42. [42] Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990;10:240-245.
43. [43] Seed M, Hopplicher F, Reaveley D, et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolaemia. N Engl J Med 1990;322:1494-1499.
44. [44] Wiklund O, Angelin B, Oloffson S, et al. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet 1990;2:1360-1363.
45. [45] Cremer P, Nagel D, Labrot B, et al. Lipoprotein(a) Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest; 24:444-453.
46. [46] Soma MR, Osnago-Gadda I, Paoletti R, et al. The lowering of lipoprotein(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med 1993;153;1462-1468.
47. [47] Mendoza S, Velazquez E, Osona A, Hamer T, Glueck CJ. Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein(a). J Lab Clin Med 1994;123:837-841.